Tags : Rare Disease Portfolio

Therachon Acquires GLyPharma Therapeutic to Expand its Rare Disease Portfolio

Shots: Therachon gains exclusive commercialization and development rights to apraglutide, initially developed by Ferring Pharma and was exclusively licensed by GLyPharma in 2012. Novo Holdings to fund the transaction with $60M The focus of the agreement is to improve QoL by providing novel and efficacious therapies for rare conditions including short bowel syndrome(SBS) and rare […]Read More